Tags

Type your tag names separated by a space and hit enter

Controlled clinical trial of cannabidiol in Huntington's disease.

Abstract

Based on encouraging preliminary findings, cannabidiol (CBD), a major nonpsychotropic constituent of Cannabis, was evaluated for symptomatic efficacy and safety in 15 neuroleptic-free patients with Huntington's Disease (HD). The effects of oral CBD (10 mg/kg/day for 6 weeks) and placebo (sesame oil for 6 weeks) were ascertained weekly under a double-blind, randomized cross-over design. A comparison of the effects of CBD and placebo on chorea severity and other therapeutic outcome variables, and on a Cannabis side effect inventory, clinical lab tests and other safety outcome variables, indicated no significant (p greater than 0.05) or clinically important differences. Correspondingly, plasma levels of CBD were assayed by GC/MS, and the weekly levels (mean range of 5.9 to 11.2 ng/ml) did not differ significantly over the 6 weeks of CBD administration. In summary, CBD, at an average daily dose of about 700 mg/day for 6 weeks, was neither symptomatically effective nor toxic, relative to placebo, in neuroleptic-free patients with HD.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Pharmacology/Toxicology, University of Arizona, Tucson 85721.

    , , , , , ,

    Source

    MeSH

    Adolescent
    Adult
    Aged
    Cannabidiol
    Double-Blind Method
    Female
    Humans
    Huntington Disease
    Male
    Middle Aged
    Psychomotor Performance

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    1839644

    Citation

    Consroe, P, et al. "Controlled Clinical Trial of Cannabidiol in Huntington's Disease." Pharmacology, Biochemistry, and Behavior, vol. 40, no. 3, 1991, pp. 701-8.
    Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav. 1991;40(3):701-8.
    Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., ... Schram, K. (1991). Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacology, Biochemistry, and Behavior, 40(3), pp. 701-8.
    Consroe P, et al. Controlled Clinical Trial of Cannabidiol in Huntington's Disease. Pharmacol Biochem Behav. 1991;40(3):701-8. PubMed PMID: 1839644.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Controlled clinical trial of cannabidiol in Huntington's disease. AU - Consroe,P, AU - Laguna,J, AU - Allender,J, AU - Snider,S, AU - Stern,L, AU - Sandyk,R, AU - Kennedy,K, AU - Schram,K, PY - 1991/11/1/pubmed PY - 1991/11/1/medline PY - 1991/11/1/entrez SP - 701 EP - 8 JF - Pharmacology, biochemistry, and behavior JO - Pharmacol. Biochem. Behav. VL - 40 IS - 3 N2 - Based on encouraging preliminary findings, cannabidiol (CBD), a major nonpsychotropic constituent of Cannabis, was evaluated for symptomatic efficacy and safety in 15 neuroleptic-free patients with Huntington's Disease (HD). The effects of oral CBD (10 mg/kg/day for 6 weeks) and placebo (sesame oil for 6 weeks) were ascertained weekly under a double-blind, randomized cross-over design. A comparison of the effects of CBD and placebo on chorea severity and other therapeutic outcome variables, and on a Cannabis side effect inventory, clinical lab tests and other safety outcome variables, indicated no significant (p greater than 0.05) or clinically important differences. Correspondingly, plasma levels of CBD were assayed by GC/MS, and the weekly levels (mean range of 5.9 to 11.2 ng/ml) did not differ significantly over the 6 weeks of CBD administration. In summary, CBD, at an average daily dose of about 700 mg/day for 6 weeks, was neither symptomatically effective nor toxic, relative to placebo, in neuroleptic-free patients with HD. SN - 0091-3057 UR - https://www.unboundmedicine.com/medline/citation/1839644/Controlled_clinical_trial_of_cannabidiol_in_Huntington's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0091-3057(91)90386-G DB - PRIME DP - Unbound Medicine ER -